Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEPIVANCE vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
FDA-approved: To decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support.,Off-label: Prevention of oral mucositis in other cancers; management of acute radiation-induced mucositis.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life is approximately 4.5 hours in healthy adults. In patients with renal impairment (Cr Cl <30 m L/min), half-life is prolonged up to 2-fold, requiring dose adjustment. The half-life supports once-daily dosing for 3 consecutive days before chemotherapy.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Metabolized via proteolytic degradation; no specific CYP450 involvement.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Primarily renal; approximately 90% of the dose is excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Minimal biliary/fecal elimination (<5%).
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Approximately 95% bound to plasma proteins, primarily albumin.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Volume of distribution at steady state (Vd_ss) is approximately 0.2 L/kg, indicating limited extravascular distribution, consistent with a large protein-bound molecule. Does not distribute extensively into tissues.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Subcutaneous administration: Absolute bioavailability is approximately 90% compared to intravenous administration. Not available orally; only given subcutaneously.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
No dose adjustment is recommended for renal impairment, but monitor serum creatinine.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
No specific dose adjustment for Child-Pugh class A or B; use caution in severe impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Safety and efficacy not established; no recommended pediatric dose.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
No specific dose adjustment, but consider age-related renal and hepatic function decline.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
None.
None
Potential for stimulation of epithelial tumor growth (use caution in patients with non-hematologic malignancies).,Risk of allergic reactions including anaphylaxis.,May cause oral mucosal thickening and dental abnormalities.,Avoid use within 24 hours before or after myelotoxic chemotherapy.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Hypersensitivity to palifermin or any excipients.,Concurrent use within 24 hours of myelotoxic chemotherapy.
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
No specific food interactions have been reported for KEPIVANCE. Maintain adequate nutrition and hydration as recommended by your healthcare provider.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was not teratogenic in rats or rabbits at doses up to 100 mg/kg/day (IV), which produced exposures approximately 40 and 80 times the human exposure at the recommended clinical dose of 60 mcg/kg/day, based on AUC. However, there are no human data. Risk in first trimester: unknown; second and third trimesters: unknown.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
It is not known whether palifermin is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from palifermin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
No pharmacokinetic data in pregnancy. No dose adjustment recommendations are provided for pregnancy; use only if clearly needed.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor used to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy requiring hematopoietic stem cell support. Administer as a 3-day course of 60 mcg/kg/day IV bolus for 3 consecutive days before and 3 consecutive days after myelotoxic therapy. Must be given at least 24 hours before and after chemotherapy; do not administer within 24 hours of chemotherapy due to risk of enhanced cytotoxicity. Monitor for skin reactions, oral/perioral edema, and taste alteration. Contraindicated in patients with known hypersensitivity to E. coli-derived proteins.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
KEPIVANCE reduces the severity and duration of mouth sores caused by high-dose chemotherapy.,It is given as a short intravenous infusion once daily for 3 days before and 3 days after your chemotherapy.,You may experience swelling of the mouth, tongue, or lips; skin rash; or changes in taste. Report these to your healthcare team.,Do not receive KEPIVANCE within 24 hours before or after chemotherapy.,Inform your doctor if you have any allergies, especially to E. coli-derived products.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEPIVANCE vs CARISOPRODOL COMPOUND, answered by our medical review team.
KEPIVANCE is a Growth Factor that works by Kepivance (palifermin) is a recombinant human keratinocyte growth factor (KGF) that binds to the KGF receptor, a splice variant of fibroblast growth factor receptor 2 (FGFR2b), stimulating proliferation, differentiation, and migration of epithelial cells, including those in the gastrointestinal tract.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEPIVANCE and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEPIVANCE is: 60 mcg/kg/day intravenously for 3 consecutive days before and 3 consecutive days after myelotoxic therapy.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEPIVANCE and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEPIVANCE is classified as Category C. KEPIVANCE (palifermin) is a recombinant human keratinocyte growth factor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, palifermin was . CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.